Skip to main content

Advertisement

SpringerLink
Log in

Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, García Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K et al (2020) Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood 136(26):3033–3040. https://doi.org/10.1182/blood.2020008150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos MV, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos MA, Gay F, Einsele H, Delforge M, Caers J et al (2021) COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol 8(12):e934–e946. https://doi.org/10.1016/S2352-3026(21)00278-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chuleerarux N, Manothummetha K, Moonla C, Sanguankeo A, Kates OS, Hirankarn N, Phongkhun K, Thanakitcharu J, Leksuwankun S, Meejun T, Thongkam A, Mongkolkaew T, Dioverti MV, Torvorapanit P, Langsiri N, Worasilchai N, Plongla R, Chindamporn A, Gopinath S et al (2022) Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. Blood Adv 6(24):6198–6207. https://doi.org/10.1182/bloodadvances.2022008530

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A, Kappes K, PVI/Seronet team, Mouhieddine TH, Wang B, Chari A, Cordon-Cardo C, Krammer F, Jagannath S, Simon V, Wajnberg A, Parekh S (2021) Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell 39(8):1028–1030. https://doi.org/10.1016/j.ccell.2021.06.014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Nooka AK, Shanmugasundaram U, Cheedarla N, Verkerke H, Edara VV, Valanparambil R, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Azeem M, Manalo J, Switchenko JM, Chang A, Linderman SL, Roback JD, Dhodapkar KM, Ahmed R, Suthar MS et al (2022) Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma. J Clin Oncol 40(26):3057–3064. https://doi.org/10.1200/JCO.21.02257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Faustini SE, Hall A, Brown S, Roberts S, Hill H, Stamataki Z, (PITCH) consortium, Jenner MW, Owen RG, Pratt G, Cook G, Richter A, Drayson MT, Kaiser MF, JLJ H (2023) Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. Br J Haematol 201(5):845–850. https://doi.org/10.1111/bjh.18714

    Article  CAS  PubMed  Google Scholar 

  7. Aleman A, Van Oekelen O, Upadhyaya B, Beach K, Kogan Zajdman A, Alshammary H, Serebryakova K, Agte S, Kappes K, Gleason CR, Srivastava K, PVI/MM/Seronet Study Group, Almo S, Cordon-Cardo C, Krammer F, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S (2022) Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. Cancer Cell 40(5):441–443. https://doi.org/10.1016/j.ccell.2022.03.013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ntanasis-Stathopoulos I, Karalis V, Gavriatopoulou M, Malandrakis P, Sklirou AD, Eleutherakis-Papaiakovou E, Migkou M, Roussou M, Fotiou D, Alexopoulos H, Theodorakakou F, Kastritis E, Iconomidou VA, Trougakos IP, Dimopoulos MA, Terpos E (2022) Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, excluding those under anti-BCMA therapy. Hemasphere 6(8):e764. https://doi.org/10.1097/HS9.0000000000000764

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Salmanton-García J, Marchesi F, Glenthøj A, Bilgin YM, van Praet J, Dávila-Valls J, Martín-Pérez S, Labrador J, van Doesum J, Falces-Romero I, Farina F, Schönlein M, Chanut M, Petzer V, Espigado I, Dargenio M, Aujayeb A, Sili U, Serrano L et al (2022) Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine: an EPICOVIDEHA report. Hemasphere 6(11):e789. https://doi.org/10.1097/HS9.0000000000000789

    Article  PubMed  PubMed Central  Google Scholar 

  10. Suribhatla R, Starkey T, Ionescu MC, Pagliuca A, Richter A, Lee LYW (2023) Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. Br J Haematol 201(5):813–823. https://doi.org/10.1111/bjh.18782

    Article  CAS  PubMed  Google Scholar 

  11. Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, van de Donk NWCJ, Ntanasis-Stathopoulos I, Vangsted AJ, Driessen C, Schjesvold F, Cerchione C, Zweegman S, Hajek R, Moreau P, Einsele H, San-Miguel J, Boccadoro M, Dimopoulos MA et al (2023) Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia 37(6):1175–1185. https://doi.org/10.1038/s41375-023-01920-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy

    Nicola Sgherza, Paola Curci, Rita Rizzi, Stefania Weigl & Pellegrino Musto

  2. Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, Bari, Italy

    Rita Rizzi, Olga Battisti, Alberto Perfetto & Pellegrino Musto

  3. Hygiene Unit, AOUC Policlinico, Bari, Italy

    Angela M. V. Larocca

  4. Department of Biomedical Sciences and Human Oncology, “Aldo Moro” University School of Medicine, Bari, Italy

    Maria Chironna & Silvio Tafuri

Authors
  1. Nicola Sgherza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Curci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rita Rizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olga Battisti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alberto Perfetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stefania Weigl
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Angela M. V. Larocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria Chironna
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Silvio Tafuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pellegrino Musto
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

PM and NS conceived and led the project; NS conducted database building, extraction, and coding; NS queried and analyzed the data; PM and NS wrote the main manuscript text and created table. All authors made a substantial intellectual contribution to the study, interpreted the data, discussed the results, and reviewed and approved the final version of the manuscript.

Corresponding authors

Correspondence to Nicola Sgherza or Pellegrino Musto.

Ethics declarations

Ethical approval

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Consent to participate

Informed consent was obtained from all patients for being included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sgherza, N., Curci, P., Rizzi, R. et al. Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases. Ann Hematol 103, 351–355 (2024). https://doi.org/10.1007/s00277-023-05484-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05484-z

Keywords

Search

Navigation